Elecoglipron
Sources
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07667803
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 4500. Conditions Weight Management. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunc
ClinicalTrials.gov NCT07667803 protocol and results modules
registry, as of 2026-10-01Stale
https://clinicaltrials.gov/study/NCT07775404
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 351. Conditions Obesity; Overweight. The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.
ClinicalTrials.gov NCT07775404 protocol and results modules
registry, as of 2026-09-16Stale
https://clinicaltrials.gov/study/NCT07723833
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 152. Conditions Healthy Participants. The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
ClinicalTrials.gov NCT07723833 protocol and results modules
registry, as of 2026-08-28Stale
https://clinicaltrials.gov/study/NCT07534592
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 48. Conditions Healthy Participants. The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
ClinicalTrials.gov NCT07534592 protocol and results modules
publication, as of 2026-06-18Stale
https://pubmed.ncbi.nlm.nih.gov/42259337/
(VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction, in development for weight management in people living with obesity or o
PMID 42259337